1056629-32-3Relevant academic research and scientific papers
Pyrrolidine and thiazolidine compounds
-
Page/Page column 10;11, (2008/06/13)
Compounds of formula (I): wherein: X1 represents an atom or group selected from CR4aR4b, O, S(O)q1 and NR5, wherein R4a, R4b, q1 and R5 are as defined in the description, m1 represents zero or an integer from 1 to 4 inclusive, m2 represents an integer from 1 to 4 inclusive, n1 and n2, which may be identical or different, each represent an integer from 1 to 3 inclusive, R1 represents hydrogen or a group selected from carboxy, alkoxycarbonyl, optionally substituted carbamoyl and optionally substituted alkyl, R2 represents hydrogen or alkyl, Ak represents an optionally substituted alkylene chain, p represents zero, 1 or 2, R3 represents hydrogen or cyano, X2 and X3, which may be identical or different, each represent either S(O)q2, or CR6aR6b, wherein q2, R6a and R6b are as defined in the description, its optical isomers, where they exist, and its addition salts with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful as DPP-IV inhibitors.
Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: Design of potent antagonists containing the 3-azaspiro[5.5]undec-9-yl template
Pandey,Seroogy,Volkots,Smyth,Rose,Mehrotra,Heath,Ruhter,Schotten,Scarborough
, p. 1293 - 1296 (2007/10/03)
The synthesis and biological activity of novel glycoprotein IIb-IIIa anatagonists containing 3-azaspiro[5.5]undec-9-yl nucleus are described. The potent activity of these compounds as platelet aggregation inhibitors demonstrates the utility of the monoaza
